Amgen Biotechnologiasp. z o.o.
Agents specialised in the sale of other particular products
KRS: NIP: REGON:
Overview
Status
Active
Registry date
2011-09-26
Share capital
5,000.00 PLN
Registered address
ul. Puławska 145, 02-715 Warszawa, Poland
Electronic delivery address
AE:PL-17954-92527-WFECC-06
Financials
Revenue history (in m)
Filing timeliness
1 of 6 financial statements was filed late (for 2021, 42 days late). All were audited by a statutory auditor.
- 202525/05/2026
- 202411/07/2025
- 202321/06/2024
- 202206/06/2023
- 202126/08/2022
- 202028/06/2021
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 14.25mMedianUSD 226.53kAverageUSD 2.28m
Net profit
This companyUSD 958.99kMedianUSD 6.25kAverageUSD 141.69k
Operating costs
This companyUSD 12.99mMedianUSD 187.76kAverageUSD 2.07m
Assets
This companyUSD 8.12mMedianUSD 163.28kAverageUSD 1.33m
Industry
Authorized Representatives
Agnieszka Jolanta Krawczyk – Attorney-in-fact (joint)
Magdalena Chrobot Osóbka – Attorney-in-fact (joint)
Omari Clinton Wise – Attorney-in-fact (joint)
Gilles Marrache – Management Board Member
Krisztian Szabolcs Toka – Management Board Member
Manner of representation
The company is represented by two members of the management board acting jointly, or by a member of the management board acting jointly with a commercial proxy.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Amgen Worldwide Holdings B.v. | 99 | $1,337.12 | 99% |
Others | 1 | $13.51 | 1% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2011-09-20.
42 1030 1508 0000 0008 1601 2007
20 1030 1508 0000 0008 1601 2015
Debt
No entries in the National Debtors Register (KRZ).
Real estate
| Type | Amount |
|---|---|
Buildings and premises | PLN 36,548PLN 36,548 |
Public aid
No public aid cases recorded in the last 10 years.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Grupa Handlowa Sangroupsp. z o.o. | $46,651,149.03 | sangroup.pl | ||
| Midas Pharma Polskasp. z o.o. | $20,847,894.51 | midas-pharma.com | ||
| SynektikS.A. | $20,028,244.70 | synektik.pl | ||
| Coltex Rogalasp. j. | $15,262,866.13 | coltex.com.pl | ||
| Zehnder Polskasp. z o.o. | $14,837,769.96 | zehnder.pl | ||
| Star Telecomsp. z o.o. | $8,529,133.88 | startelecom.pl | ||
| Energy Centersp. z o.o. | $6,768,722.42 | energy-center.pl | ||
| Sądkiewicz-Servicesp. k. | $3,829,148.99 | sadkiewicz-service.eu | ||
| Symkomsp. z o.o. | $3,686,071.92 | symkom.pl | ||
| Business Solutions & Supportsp. z o.o. | $3,448,733.42 | motopatent.pl |
Change history
| Date | Event | |
|---|---|---|
| 2025-11-05 | Switch to PKD 2025 (2 PKD 2007 codes → 2 PKD 2025 codes) | |
| 2019-02-05 | Address change (Domaniewska 50, 02-672, Warszawa → Ul. Puławska 145, 02-715, Warszawa) | |
| 2015-09-03 | PKD change (Removed: 45 codes) | |
| 2013-02-20 | Address change (Złota 59, 00-120, Warszawa → Domaniewska 50, 02-672, Warszawa) | |
| 2012-01-30 | Address change (Emilii Plater 53, 00-113, Warszawa → Złota 59, 00-120, Warszawa) |
FAQ
The main business activity of Amgen Biotechnologia focuses on agents involved in the sale of specialised goods.
The company was registered in the Polish National Court Register (KRS) on September 26, 2011.
The headquarters is located at: ul. Puławska 145, 02-715 Warszawa.
The share capital of the company is PLN 5,000 (approx. $1,351).
The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.
The company reported a revenue of USD 14,253,529 in 2025, which is an increase of 9.8% compared to 2024.
Yes, the company recorded a net profit of USD 958,992 in 2025, meaning the company increased its profit by 24.5%.
The largest operating cost category falls under employee remuneration. This category amounted to USD 6,265,147 in 2025, representing 48% of all operating expenses.
Last updated: 2026-10-07